
    
      A randomised, double blind, placebo-controlled, double dummy, 4-way cross-over, dose
      ascending study to assess the safety, tolerability, pharmacodynamics and pharmacokinetics of
      single inhaled doses of GSK573719 (3 escalating mcg doses will be used) and tiotropium
      bromide (18Âµg) via DPI in COPD patients
    
  